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Abstract
A subset of paediatric sarcomas are characterized by chromosomal translocations encoding specific oncogenic transcription
factors. Such fusion proteins represent tumor specific therapeutic targets although so far it has not been possible to directly
inhibit their activity by small-molecule compounds. In this study, we hypothesized that screening a small-molecule library
might identify already existing drugs that are able to modulate the transcriptional activity of PAX3/FOXO1, the fusion
protein specifically found in the pediatric tumor alveolar rhabdomyosarcoma (aRMS). Towards this end, we established a
reporter cell line based on the well characterized PAX3/FOXO1 target gene AP2ß. A library enriched in mostly FDA approved
drugs was screened using specific luciferase activity as read-out and normalized for cell viability. The most effective inhibitor
identified from this screen was Fenretinide. Treatment with this compound resulted in down-regulation of PAX3/FOXO1
mRNA and protein levels as well as in reduced expression of several of its direct target genes, but not of wild-type FOXO1, in
a dose- and time-dependent manner. Moreover, fenretinide induced reactive oxygen species and apoptosis as shown by
caspase 9 and PARP cleavage and upregulated miR-9. Importantly, it demonstrated a significant anti-tumor effect in vivo.
These results are similar to earlier reports for two other pediatric tumors, namely neuroblastoma and Ewing sarcoma, where
fenretinide is under clinical development. Our results suggest that fenretinide might represent a novel treatment option
also for translocation-positive rhabdomyosarcoma.
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Introduction
Prognosis of cancer patients can be strongly improved through
optimization of therapeutic regimens. However, to increase
survival rates it is necessary to identify and develop further
alternative treatment strategies as well as to minimize treatment
related side-effects, a matter of great importance for childhood
cancer long-term survivors. In our studies, we use the pediatric
tumor rhabdomyosarcoma (RMS) as a model system. RMS
accounts for 5% to 8% of all pediatric malignancies and is the
most common soft tissue sarcoma diagnosed in children [1].
Histopathologically, RMS is classified into two main subtypes,
embryonal RMS (eRMS) and alveolar RMS (aRMS). eRMS
represents the majority of RMS cases, ,60%, and shows a more
favorable prognosis [2]. aRMS is less frequent, more aggressive,
appears at unfavourable locations, frequently presents with
metastasis and displays resistance to conventional chemo- and
radiotherapy [3]. The majority of aRMS is characterized by the
specific chromosomal translocation t(2;13)(q35;q14) generating the
chimeric transcription factor PAX3/FOXO1 [4].
The oncogenic role of PAX3/FOXO1 depends on deregulation
of PAX3 target genes as well as alteration of gene expression
patterns [5], [6]. Down-regulation or inhibition of PAX3/FOXO1
inhibits proliferation and induces apoptosis in aRMS cells [7], [8],
[9], hence the aRMS tumor cells become dependent on fusion
protein expression. PAX3/FOXO1 transcriptional activity is
subject to modulation at different molecular levels such as e.g.
post-translational modifications. Phosphorylation of several serine
residues in a peptide located between the two DNA-binding
domains of PAX3 is required for efficient target gene activation
[10]. Furthermore, stability of the fusion protein itself is subject to
regulation via the proteasome pathway [11], [12]. Thus,
oncogenic fusions are necessary for maintaining the malignant
phenotype of aRMS which spots them as being ideal targets for
development of a directed therapeutic approach.
Dose intensification of conventional multimodal chemothera-
peutic regimens confers small survival benefits for RMS patients
with metastatic or recurrent disease [13], [14]. Unfortunately,
there are no alternative treatment strategies so far that would
target tumor cells more specifically and effectively [15]. Therefore,
we aimed at identifying drugs capable to modulate the transcrip-
tional activity of PAX3/FOXO1 irrespective of their mode of
action. In this study, we used a small-molecule compound library
coupled with a specific reporter assay to identify fenretinide as the
most promising drug inhibiting PAX3/FOXO1 activity. Fenreti-
nide (N-(4-hydroxyphenyl) retinamide) is a synthetic vitamin A
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analogue with chemopreventive [16] and known anti-tumoral
activity [17]. It shows a wide range of effects in different
carcinomas and importantly, is already under clinical development
in several childhood malignancies [18]. Hence, our study identifies
with aRMS yet another pediatric tumor that might be sensitive to
fenretinide treatment.
Materials and Methods
Cell Lines and Reagents
aRMS cell lines Rh4 [19] and Rh41 [20] were kindly provided
by Dr. P. Houghton (Nationwide Children’s Hospital, Columbus,
Ohio) and RMS13, Rh30 (aRMS), RD (eRMS) and HEK 293
cells were obtained from American Type Culture Collection (LGC
Promochem, Molsheim, France). Ruch2 (eRMS, botryoid sub-
type) was established in our laboratory [21]. ES cell lines, TC71
and A673, were obtained from American Type Culture Collec-
tion. All cells were maintained in high glucose DMEM
(Bioconcept, Allschwil, Switzerland) supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin, in 5% CO2 at 37uC. The small-compound
library (LOPAC 1280), fenretinide, phorbol 12-myristate 13-
acetate (TPA) and L-ascorbic acid were purchased from Sigma-
Aldrich (Buchs, Switzerland).
Drug-screening
PAX3/FOXO1 luciferase reporter was based on the well
characterized AP2beta promoter and generated as previously
described in the pGL3 vector [10], [11]. The pGL3 enhancer
vector was used as control. Vectors were electroporated individ-
ually into Rh4 cells using the AMAXA system (Lonza, Cologne,
Germany) (Program O17, buffer R). Selection of stably transfected
cells as pool was performed with 1 mg/ml G-418 sulfate
(Promega, Wallisellen, Switzerland). 56103 Rh4-AP2b-LF or
SV40-LF cells were plated into 96 well plates and treated 24
hours later with the small-molecule compounds at a final
concentration of 5 mM during 24 hours. Afterwards, luciferase
activity was measured (Luciferase Assay System, Promega)
according to manufacturers protocol in parallel with measuring
proliferation rates (WST-1) (Roche, Basel, Switzerland) in the
same wells to correct for cell viability.
Proliferation Assay
Twenty-four hours after seeding in 96-well plates, cells (56103
per well) were treated with increasing concentrations of fenretinide
(Sigma-Aldrich) in a final volume of 100 mL medium including
10% serum for 72 hours. WST-1 assay (Roche) was then
performed according to the manufacturer’s instructions. For each
concentration, the percentage of viable cells compared with
control cells was plotted against the logarithm of drug concentra-
tions. IC50 values were then calculated by nonlinear regression
curve fitting using GraphPad Prism software (GraphPad Software
Inc., San Diego, CA, USA).
Quantitative Real Time PCR
Total RNA was extracted with the RNeasy Kit (Qiagen,
Hombrechtikon, Switzerland). Following DNase treatment, sam-
ples were reverse-transcribed with Oligo (dT) primers using the
Omniscript Reverse Transcription Kit (Qiagen). Quantitative
reverse transcription-PCR (qRT-PCR) was performed under
universal cycling conditions on an ABI 7900HT instrument using
commercially available target probes (PAX3, AP2b, FGFR2,
FGFR4, CB1, p8 and Bcl-2) and mastermix (all from Applied
Biosystems, Rotkreuz, Switzerland). Cycle threshold (CT) values
were normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Experiments were performed in triplicates. Relative
expression levels of the target genes among the different samples
were calculated using the DDCT method [22]. Mean values and
standard deviations were calculated based on the results of three
biological replicates at least.
Western Blotting
107 Cells were denatured in RIPA buffer supplemented with
1 mM PMSF (Roche) and Roche Complete Protease inhibitor
(Roche) for 15 minutes on ice. Total cell extract was separated on
4–12% NuPAGE Bis-Tris gels (Invitrogen, Basel, Switzerland) and
blotted on nitrocellulose membranes (Whatman Schleicher &
Figure 1. Schematic representation of the screening strategy based on a target gene (AP2b) driven reporter aRMS cell line.
doi:10.1371/journal.pone.0055072.g001
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Schuell, Sigma-Aldrich). Blots were blocked with 5% BSA,
incubated with the first antibody overnight at 4uC and with the
corresponding HRP-conjugated secondary antibody for one hour
at RT. Primary antibodies used were: FOXO1 (C20; 1:500) from
Santa Cruz Biotechnology (Heidelberg, Germany), and Caspase 9,
recognizing both the pro- and cleaved form, (1:1000) and PARP
(1:1000) from Cell Signaling (Allschwil, Switzerland). ß-actin
antibody (A2103; 1:2000; Sigma) was used as protein loading
control. Enhanced chemiluminescence detection system (Super-
Signal West Femto, Pierce, Thermo Scientific, Lausanne, Swit-
zerland) was used for signal detection.
Apoptosis Assay
Apoptosis was measured after treatment of Rh4 and RMS13
cells with fenretinide for 48 and 96 hrs. Apoptotic index was
assessed by flow cytometry, using AnnexinV/FITC (BD, Schwe-
chat, Austria). Data acquisition and analysis were done in a LSR
Fortessa Cytometer (BD) using DiVa 6.x software (BD).
Reactive Oxygen Species (ROS) Generation
Rh4 and RMS13 cells were seeded and treated with fenretinide
(IC50) for 24 hours. Afterwards they were incubated for one hour
with the profluorescent, lipophilic dye H2-DCF-DA (dihydrodi-
Figure 2. Small-molecule drug screening identifies fenretinide as promising candidate drug. A) Fenretinide inhibits reporter gene
activity. Rh4-AP2b-LF cells were treated with the small-molecule compound library at a final concentration of 5 mM during 24 hours and luciferase
activity (light grey bars) measured as read-out of the screening together with proliferation (dark grey bars) by WST-1 assay. Actual values for the ten
top-ranked compounds are shown relative to untreated controls. B) Proliferation and reporter gene activity in Rh4-AP2b-LF compared to SV40-LF cells
after fenretinide treatment for 24 hours are shown. Representative values of three independent experiments. Columns, mean; bars, s.d.
doi:10.1371/journal.pone.0055072.g002
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chlorofluorescein diacetate) (Invitrogen) which can diffuse through
the cell membrane. H2-DCF-DA final concentration was 20 mM.
After reaction with ROS, primarily hydrogen peroxide (H2O2),
DCF fluorescence (max. emission , 530 nm) was measured in a
microplate reader (Tecan, Ma¨nnedorf, Switzerland) [23].
Analysis of miR-9 Expression
RNA was extracted with the miRNeasy kit (Qiagen) following
manufacturers protocol. Following DNase treatment, samples
were reverse-transcribed using the TaqMan MicroRNA Assay Kit
(Applied Biosystems). Quantitative reverse transcription-PCR
(qRT-PCR) was performed on an ABI 7900HT instrument using
commercially available target probe (miR-9) and mastermix (all
from Applied Biosystems). Cycle threshold (CT) values were
normalized to snRNA RNU6B. Relative expression levels of
miR-9 among the different samples were calculated using the
DDCt method [22]. Experiments were performed in triplicates.
Mean values and standard deviations were calculated based on the
results of two biological replicates.
In vivo Assay
Xenograft experiments were approved by the veterinary office
of the Canton of Zurich. HEK293 GPG cells were transfected
with the plasmid pLIB-LN (Takara Bio Europe/Clontech,
Saint-Germain-en-Laye, France) expressing luciferase. After col-
lection of the retroviral supernatant, Rh4 cells were infected and
selection started 48 hours later with G418 (Promega). 36106
Rh4-luc cells were re-suspended in PBS and injected s.c into the
flanks of 6 weeks old NOD/Scid Il2rg2/2 (NSG) mice (Charles
River, Sulzfeld, Germany). Mice bearing tumors were treated
intraperitoneally after the tumor reached a volume of at least
100 mm3 with either sterile 0.9% NaCl or fenretinide at a dose
of 20 mg/kg daily during two weeks. 5 mg fenretinide were
dissolved in 106 ml sterile ethanol and then in 1144 ml sterile
0.9% NaCl solution to achieve a final concentration of 4 mg/
ml. Tumor growth was measured every day and mice were
euthanized when reaching a tumor volume of 1500 mm3.
Tumor size was determined either by measuring two diameters
(d1, d2) in right angles using a digital caliper and volume was
calculated using the formula V= (4/3) p r3, whereby
r = (d1+d2)/4 or by i.p. injection of D-luciferin potassium salt
(Caliper Life Sciences, Oftringen, Switzerland), resuspended in
sterile aqua ad injectabilia (Sintetica, Mendrisio, Switzerland) to
a final concentration of 15 mg/ml, at a dose of 10 ml/g body
weight. Tumors were monitored in vivo after administration
using an IVIS Lumina XR imaging system (Caliper Life
Sciences). Total flux (photons/second) was used as the unit of
measure. Every treatment group consisted of 3 mice.
Immunohistochemistry
Mice were sacrificed and tumors obtained by dissection fixed in
PFA. Immunohistochemical analysis was done as described before
[10]. H&E, Ki67 and cleaved Caspase 3 were stained. For
quantitative evaluation, the number of positive cells was counted
in ten randomly selected visual fields in non-necrotic areas of the
tumor using Image J software. In the case of quantitative analysis
of Caspase 3 positive cells, due to the presence of strong staining
on the edges of the non treated tumor sections that likely
represents an artefact, ten randomly selected visual fields from the
inner tumor mass were included. Two-tailed, unpaired t test was
used for statistical analysis. The level of significance was set at
p,0.05.
Statistical Analyses
IC50 values were calculated by nonlinear regression curve
fitting using GraphPad Prism software (GraphPad Software Inc.).
Statistical significance was tested with unpaired two-tailed
Table 1. LOPAC small-molecule compound library screening hit list.
Compound Ratioa Description
Retinoic acid p-hydroxyanilide 4,51 Vitamin A acid analog
(6)-Quinpirole dihydrochloride 4,29 Dopamine receptor agonist
ML 10302 4,04 Serotonin receptor agonist
Propantheline bromide 3,95 Muscarinic acetylcholine receptor antagonist
N,N,N’,N’-Tetramethylazodicarboxamide 3,84 Thiol-oxidizing agent
Etoposide 3,8 Topoisomerase II inhibitor
L-162,313 3,67 Angiotensin II receptor agonist
9-cyclopentyladenine 3,43 Adenylyl cyclase inhibitor
R(2)-Isoproterenol (+)-bitartrate 3,37 Adrenoceptor agonist
BRL 50481 3,27 Phosphodiesterase 7 inhibitor
aRatio = Proliferation rate/Luciferase activity as compared to the non-treated RH4-AP2ß-LF cells (5 mM incubation for 24 hours).
doi:10.1371/journal.pone.0055072.t001
Table 2. Fenretinide affects aRMS cell proliferation in the low
mM range.
Cell line Fenretinide IC50a Type
Rh4 2,27 mM Alveolar
Rh30 9,42 mM Alveolar
RMS13 6,43 mM Alveolar
Rh41 5,48 mM Alveolar
RD 31,48 mM Embryonal
Ruch-2 21,21 mM Embryonal
A673 1,09 mM Ewing Sarcoma
TC71 2,13 mM Ewing Sarcoma
aIC50 values were calculated by nonlinear regression curve fitting using
GraphPad Prism software.
doi:10.1371/journal.pone.0055072.t002
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Student’s t-tests and a p,0,05 was considered statistically
significant.
Results
Fenretinide Modulates PAX3/FOXO1 Target Gene
Expression
To identify compounds that might be able to modulate
expression of PAX3/FOXO1 target genes either directly or
indirectly, we screened a small-molecule compound library
(LOPAC 1280, Sigma) which covers 1280 different drug-like
and well annotated compounds including all major drug types. We
used an endogenous cellular model, Rh4, which represents a
PAX3/FOXO1 bearing aRMS cell with a transcription profile
very similar to tumor biopsies [24] (screening strategy outlined in
Figure 1). As a read-out system we simultaneously assessed cell
viability together with a well established and highly sensitive
luciferase reporter assay based on the AP2ß target gene promoter
to monitor fusion protein activity [10], [11]. For the primary
screen, Rh4-AP2ß-LF cells were treated with the compounds at a
final concentration of 5 mM for 24 hours. Luciferase activity was
measured as primary read-out and corrected for cell number
measured in the same wells. Using a cut-off of 65% reduction in
luciferase activity, we identified 104 compounds fulfilling all
Figure 3. Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. Rh4 and RMS13 cells were treated for 24
hours (A) and 48 hours (B) with different concentrations of fenretinide (0.5–1–5 mM, as indicated). PAX3/FOXO1, AP2ß, FGFR2 and FGFR4 mRNA
expression levels were measured with qRT–PCR. CT values were normalized to GAPDH. Representative values of at least two independently carried
out experiments. Columns, mean; bars, s.d. *** p,0,001 ** p,0,01 * p,0,05 compared to mock treated cells (wt). C) Western blot analysis of PAX3/
FOXO1 protein expression in Rh4 and RMS13 cells at different time points of treatment and different doses of fenretinide (1 mM-IC50-IC95), as
indicated. PAX3/FOXO1 was detected with a FOXO1 antibody and actin was used as loading control. D) Fenretinide did not decrease mRNA levels of
FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC50 concentration of fenretinide during different time points (24–48–72
hours). CT values were normalized to GAPDH. Representative values of at least two independent experiments. Columns, mean; bars, s.d. E) eRMS RD
cells were treated during 24 hours with different concentrations of fenretinide (0.5–1–5 mM, as indicated). FGFR4 mRNA expression was measured by
qRT-PCR. CT values were normalized to GAPDH. Representative values of at least two independently carried out experiments. Columns, mean; bars,
s.d.
doi:10.1371/journal.pone.0055072.g003
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criteria. Among them are molecules with a broad range of
mechanisms such as kinases or topoisomerase II inhibitors as well
as compounds related to nitric oxide. In a secondary screen, we re-
measured all 104 compounds together with a SV40-driven
luciferase reporter to eliminate compounds directly affecting
luciferase activity. Of the remaining 52 compounds, the top-
ranked 10 compounds with the highest ratio proliferation/
luciferase activity were then re-tested using different concentra-
tions (5, 1 and 0.5 mM) and time points (24, 48, 72 hours).
Fenretinide (retinoic acid p-hydroxyanilide) ranked as the most
effective small-molecule compound affecting AP2ß-driven lucifer-
ase activity (Table 1 and Figure 2A). Fenretinide-treated cells
exerted a reduction in luciferase activity of more than 80%
compared to empty vector treated cells whereas proliferation was
similar for both cells at this time point (Figure 2B). Hence,
fenretinide treatment provoked a non-cytotoxic repression of the
PAX3/FOXO1 target gene AP2ß.
Fenretinide Affects aRMS Cell Proliferation at the Low mM
Range
To investigate whether fenretinide specifically affects aRMS
cells, we next treated four aRMS cell lines (Rh4, Rh41, RMS13,
Rh30) with increasing concentrations of fenretinide for 72 hours to
determine IC50 concentration in comparison to two eRMS cells
(RUCH-2 and RD). Fenretinide reduced the number of viable
cells in all four aRMS cell lines tested with lower IC50 values (IC50
range, 2.27–9.42 mM) compared to those of embryonal origin
(Ruch-2, RD) that lack PAX3/FOXO1 expression (IC50 range,
21.21–31.48 mM) (Table 2). Rh4 was the aRMS cell line most
sensitive to fenretinide (2,27 mM). As positive control, sensitivity of
two ES cell lines, A673 and TC71, was in a very similar range to
what has been already reported [25]. Taken together, these results
reveal a good sensitivity of translocation-positive RMS cell lines
towards fenretinide treatment.
Fenretinide Reduces Expression of PAX3/FOXO1 mRNA
To detect early effects of fenretinide on mRNA expression levels
of additional PAX3/FOXO1 target genes as well as PAX3/
FOXO1 itself, we analyzed mRNA expression by qRT-PCR 24
hours after treatment with different concentrations of the drug (5,
1 and 0.5 mM). Fentretinide led to significant repression of both
PAX3/FOXO1 expression and its target genes AP2ß [24],
fibroblast growth factor receptor 2 (FGFR2) [24], and fibroblast
growth factor receptor 4 (FGFR4) [26], following a dose-
dependent course in Rh4 cells. Similar observations were made
for RMS13 cells (Figure 3A). Analysis after 48 hours of treatment
using lower doses of fenretinide (1 and 0.5 mM) revealed that
PAX3/FOXO1 mRNA levels together with its targets AP2ß and
FGFR4 were still repressed (Figure 3B). These findings were
further corroborated on the protein level in both Rh4 and RMS13
cells (Figure 3C). They suggest that fenretinide treatment affects
PAX3/FOXO1 mRNA and protein levels and that of several
target genes in translocation-positive RMS cells.
Figure 4. Fenretinide induces ROS in alveolar rhabdomyosarcoma cell lines. A) Rh4 and RMS13 cells were treated for 24 hours with an IC50
concentration of fenretinide. H2-DCF-DA was added thereafter for 1 hour. Hydrogen peroxide was added to a final concentration of 250 mM to
enhance ROS generation. Final concentration of TPA was 1 mM. Fluorescence was analyzed at 530 nm. The means 6 standard deviations (error bars)
of three experiments are hown. Columns, mean; bars, s.d. *** p,0,001 compared to wt. B) The effect induced by fenretinide could be blocked by a
ROS inhibitor, L-ascorbic acid. Western blot analysis of Rh4 and RMS13 cells treated with IC50 fenretinide alone or a combination of IC50 fenretinide
plus 100 mM L-ascorbic acid during different time-points (24–48–72 hours). Cells treated with IC50 fenretinide plus L-ascorbic acid did not show
reduction in PAX3/FOXO1 levels.
doi:10.1371/journal.pone.0055072.g004
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To investigate the specificity of this effect we next measured
expression levels of FOXO1 in Rh4 and RMS13 cells. Using an
IC50 dose of fenretinide, we did not observe any change after 24
hours and only a minor decrease after longer treatment periods
(Figure 3D). In addition, the fusion negative eRMS cell line RD
was treated for 24 hours with different fenretinide concentrations
(5, 1 and 0.5 mM). We did not detect any change in the expression
of FGFR4 in RD cells (Figure 3E). These findings suggest that
fenretinide affects preferentially PAX3/FOXO1 and its gene
expression signature in aRMS.
Fenretinide Induces Reactive Oxigen Species (ROS) in
aRMS
To investigate whether fenretinide acts via induction of ROS
production in aRMS cells, Rh4 and RMS13 cells were treated
with an IC50 dose for 24 hours and incubated thereafter with the
dye H2-DCF-DA to evaluate intracellular ROS levels. As a
positive control for ROS generation, we stimulated cells with TPA
[27]. We observed a significant increase of ROS in both Rh4 and
RMS13 cells (Figure 4A). Treatment of both aRMS cell lines with
L-ascorbic acid, a well-known ROS inhibitor, completely abol-
ished repression of PAX3/FOXO1 protein levels (Figure 4B).
These results suggest that fenretinide might affect aRMS cells by
the same mechanism that has already been described for other
pediatric tumors such as ES and neuroblastoma [25], [28], [29].
Fenretinide Provokes Apoptosis in aRMS Cells through
Caspase 9 Activation and Bcl-2 Down-regulation
To investigate if the decrease in the number of viable cells after
fenretinide treatment was due to apoptosis induction, we
performed flow cytometry analysis with combined Annexin V-
propidium iodide staining. We observed a dose-dependent
increase in the number of cells within the apoptotic fraction
(sub-G1) in both aRMS cells. For example in Rh4 cells treated
with fenretinide at IC50 for 48 hours, the apoptotic index increased
to ,30% and could be partially blocked by addition of L-ascorbic
acid. Similar observations were made with RMS13 cells
(Figure 5A). Also, induction of pro-caspase 9 and PARP cleavage
Figure 5. Fenretinide promotes apoptosis in aRMS cells. A) FACS analysis of AnnexinV and PI stained Rh4 and RMS 13 cells after treatment
with fenretinide alone (1 mM to IC50) or a combination of IC50 fenretinide plus 100 mM ascorbic acid (ROS inhibitor) during 48 hours. Graphs show the
percentage of apoptotic cells. Representative values of at least two independently carried out experiments. Columns, mean; bars, s.d. B) Western blot
analysis of caspase 9 and PARP cleavage in Rh4 and RMS13 cells after different time points and different doses of fenretinide treatment as indicated.
Actin was used as loading control. C) Bcl-2 mRNA expression levels were determined with qRT-PCR in Rh4 and RMS13 cells treated with IC50
concentration of fenretinide at different time points as indicated. Ct values were normalized to GAPDH. Representative values of three independent
experiments. Columns, mean; bars, s.d. *** p,0,001 ** p,0,01 * p,0,05 compared to wt.
doi:10.1371/journal.pone.0055072.g005
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in a dose and time-dependent manner was observed (Figure 5B).
Next, we assessed the mRNA expression levels of the anti-
apoptotic protein Bcl-2 by qRT–PCR. Fenretinide prompted a
marked decrease in Bcl-2 levels particularly after 24 hour exposure
in both aRMS cell lines (Figure 5C). Collectively, these results
suggest that fenretinide induces apoptosis in aRMS cells via
caspase 9 activation and a marked decrease in Bcl-2 levels.
Fenretinide Induces miR-9 Expression
It has been shown previously that fenretinide is able to increase
miR-9 levels in human retinal pigment epithelial cells [30]. Hence,
we analyzed expression of miR-9 after two low dose (0.5 and
1 mM) treatment at two different time points (24 and 72 hours) by
qRT-PCR. Significant up-regulation of miR-9 was seen in both
aRMS cell lines (Figure 6A, B).
Fenretinide Delays Tumor Growth in vivo
Finally, we used an aRMS xenograft mouse model generated by
subcutaneous injection of Rh4 cells engineered to constitutively
express luciferase into immunocompromised NOD/Scidil2rg2/2
mice to analyze the effects of fenretinide in vivo. Treatment with
fenretinide at a dose of 20 mg/kg daily during two weeks
significantly slowed down tumor growth compared to control
mice both when measuring tumor volume (Figure 7A, left) as well
as luciferase activity (Figure 7B, right). To further characterize the
effect of fenretinide, tumors were isolated, paraffin-embedded and
immunohistochemically stained with the proliferation marker
Ki67 and activated caspase 3. As shown in Figure 7B, the number
of both Ki-67 and caspase 3 positive cells was clearly reduced in
the treated tumors, with large areas without positive cells.
Quantitative analysis revealed that the reduction was statistically
significant. We did also not observe any adverse physiological
effects in the treated mice. Hence, fenretinide displays an anti-
tumorigenic effect also in vivo.
Discussion and Conclusion
aRMS is in urgent need of new therapeutic approaches as
resistance to current chemotherapeutic regimens is unfortunately
common [31] and relapsed and metastatic patients show a very
poor prognosis [13], [32]. In this study, we have used a library of
1280 well characterized small-molecule compounds together with
Figure 6. Fenretinide upregulates miR-9. Rh4 and RMS13 cells were treated with different concentrations of fenretinide at two time points (0.5–
1 mM; 24–72 hours). miR-9 expression level was measured by qRT-PCR. CT values were normalized to snRNA RNU6B. Representative values of three
independently carried out experiments. Columns, mean; bars, s.d. * p,0,05 compared to wt.
doi:10.1371/journal.pone.0055072.g006
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Figure 7. Fenretinide delays tumor growth in vivo. Growth rate of Rh4 xenograft tumors in NOD/Scidil2rg2/2 mice (n = 3) treated with sterile
0.9% NaCl (control) or fenretinide (treated), Left: tumor volume was determined using a calliper, Right: tumor volumes determined according to
luminescence values measured by IVIS Lumina XR imaging system (Caliper Life Sciences). B) Immunohistological staining of Ki67 (left) and activated
caspase 3 (right) of Rh4 xenograft tumor sections treated with sterile 0.9% NaCl or fenretinide. C) Quantification of Ki67 and activated caspase 3
positive cells counted per field using Image J software in Rh4 sections of tumors treated with sterile 0.9% NaCl or fenretinide. Columns, mean; bars,
s.d. *p,0,05 compared to control mice.
doi:10.1371/journal.pone.0055072.g007
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an endogenous aRMS cellular model (Rh4) to screen for the most
active compounds. We have identified fenretinide as the most
effective agent reducing PAX3-FOXO1 levels in vitro and
decreasing tumor growth in vivo. While most of the fenretinide-
treated cells remained alive after short exposure, they already
displayed a marked reduction in AP2ß-driven luciferase activity
(up to 80% decrease) as compared to non-treated cells. Even more
striking, fenretinide treatment resulted in a significant reduction of
PAX3-FOXO1 mRNA and protein levels, and consequently
affected expression of its target genes. To our knowledge, this is the
first report of fenretinide activity in aRMS.
Fenretinide (N-(4-hydroxyphenyl)retinamide) is a synthetic
retinoid derivative that holds potential both as anticancer and
chemopreventive drug. It is well tolerated both in adult and
paediatric patients [33]. Moreover, the drug demonstrated activity
both in vitro and in vivo against a wide range of tumors [34], [35]
including childhood neuroblastoma and ES [36], [37]. Hence,
several clinical trials with fenretinide in paediatric cancer patients
are ongoing [18], [38]. Retinoic acid (RA) and derivatives such as
ATRA (all-trans-retinoic acid) and CRA (13-cis retinoic acid) have
demonstrated effects inhibiting growth and promoting differenti-
ation of some, but not all RMS cell lines [39], [40]. We have
shown that fenretinide was able to inhibit the growth of aRMS
cells at low mM concentration (Rh4 IC50 2,27 mM and RMS13
IC50 6 mM). aRMS cells were more sensitive to fenretinide than
translocation-negative eRMS cell lines. These IC50 values are very
similar to the ones already described in other paediatric neoplasias
such as rhabdoid tumors [41] and only slightly higher than in ES
cells [25].
Fenretinide alters the PAX3/FOXO1 dependent transcription-
al program since it represses PAX3/FOXO1 at both mRNA and
protein levels. Consequently, also well-defined targets such as
AP2ß, FGFR2 or FGFR4 [24], [26] are repressed. Among these,
FGFR4 is known to play an important role in aRMS since
activating mutations in its tyrosine kinase domain have been
reported in a subset of primary tumors associated with an
enhanced metastatic phenotype in xenografts [42]. AP2ß has been
validated as direct target gene mediating the anti-apoptotic and
proliferative function of PAX3/FOXO1 and FGFR2 is part of the
PAX3/FOXO1 in vivo target gene signature [24]. In Rh4 and
RMS13 cells levels of FGFR4; AP2ß and FGFR2 are diminished
by fenretinide using lower doses such as 0.5 and 1 mM and they
remained repressed for 72 hours of treatment. Fenretinide also
reduced protein levels of PAX3/FOXO1 in both cell lines and as
expected, FGFR4 protein levels were also found to be repressed
(data not shown). Fenretinide treatment also down-regulated CB1
(data not shown), another direct target gene of PAX3/FOXO1
[6], confirming an inverse correlation between these two genes
that was reported previously [43]. Fenretinide modified FOXO1
levels only minor in aRMS cells and FGFR4 expression was not
changed in eRMS cell line RD that lacks the fusion protein. Thus,
fenretinide affected PAX3/FOXO1 gene expression signature
preferentially in translocation-positive RMS cells as these effects
can not be observed in translocation-negative RMS cell lines. We
conclude that fenretinide reduces PAX3/FOXO1 levels and most
importantly PAX3/FOXO1 transcriptional activity, at least at the
level of target gene expression. However, the mechanisms leading
to reduction in PAX3/FOXO1 mRNA levels remain to be
investigated further. Since very little is known about transcrip-
tional regulation of PAX3/FOXO1 in aRMS cells, identification
of fenretinide provides a first important tool the address this issue
in the future.
Fenretinide induced apoptosis in both aRMS cell lines similar to
what has already been described in many other tumors [17].
Modulation of expression levels of anti-apoptotic genes such as
Bcl-2 has been described in leukaemia cells exposed to fenretinide
[44]. Bcl-2 expression is of significance in rhabdomyosarcoma as
high levels have been linked to poor survival and recurrence [45].
Fenretinide is able to down-regulate Bcl-2 levels in both cell lines.
Fenretinide treatment induced pro-caspase 9 cleavage as well as
caspase 3/7 activation (data not shown) in a dose and time-
dependent manner in both Rh4 and RMS13 cells. Corresponding
PARP cleavage was also observed (data not shown). Caspase 9
activation due to fenretinide treatment confirms the initiation of
the intrinsic or mitochondrial-mediated apoptotic pathway as has
been described in ES [28]. This might possibly be mediated by
generation of ROS as implicated also in other tumor cell types
analyzed and described in detail before [17] in cells including ES
[25,28]. Indeed, we could also observe increased ROS production
in aRMS cells. Processing of pro-caspase 9 and the down-
regulation of Bcl-2 and AP2ß could explain the pro-apoptotic
effect of fenretinide in aRMS cells. However, the exact mechanism
by which production of ROS might be linked to repression of
PAX3/FOXO1 and Bcl-2 need to be further investigated. When
aRMS cells were treated with L-ascorbic acid, a well-known ROS
inhibitor, fenretinide effects were completely abolished.
MicroRNAs (miRs) are small highly conserved non-coding
RNAs [46]. Deregulation of miRs expression is a common
phenomena in cancer [47] and they have emerged as promising
therapeutic targets [48]. miR-9 has been described both as tumor
suppressor [49], [50], and as an oncomiR involved in metastasis
formation [51]. A link between miR-9 and stem cells have been
reported [52], [53]. Importantly, miR-9 has been connected to
ROS generation [54], and an increase in miR-9 expression levels
has been described in human retinal epithelial cells after
fenretinide exposure [30]. Here, we could demonstrate that
fenretinide is able to increase miR-9 expression in aRMS as well.
So far this is the first description of miR-9 expression in aRMS and
its possible function in aRMS metastasis warrants further
investigation.
In vivo, fenretinide delayed tumor growth and metabolic rate in
an Rh4 mouse xenograft model. Effectiveness of fenretinide per se
has been demonstrated in vivo in a wide range of tumors such as
ovarian cancer [55], Kaposi’s sarcoma [56], retinoblastoma [57]
but also in combination with other chemotherapeutic agents as
rituximab in B-cell lymphoma [58], ABT-737 in neuroblastoma
[59] or genistein in ES xenografts [60]. Synergy of fenretinde with
ABT-737 in acute lymphoblastic leukemia cell lines depends on
Mcl-1 inactivation [61] and in neuroblastoma on Bcl-2 inhibition
[59]. The synergistic induction of apoptosis observed in ES with
fenretinide and death receptors ligands suggests another exciting
possibility [62]. Since stimulation of death receptors is also able to
induce apoptosis in aRMS, combination with fenretinide might be
indeed an interesting possibility to further improve its anti-
tumorigenic effects [63]. Hence, it will be a goal of future research
to identify drug combinations that act synergistically with
fenretinide in aRMS, especially in larger in vivo studies.
Here, we have demonstrated that fenretinide is effective in vitro
and in vivo against aRMS and warrants further investigation
especially in combination with other drugs. Unlike most other
experimental strategies which reason that an increased under-
standing of the pathobiology (target genes) would lead to
identification of active compounds, our strategy was based on a
reverse approach that has allowed us to identify already known
compounds which have not yet been tested for aRMS treatment,
such as fenretinide.
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